Jaspar Witteler1, Troels W Kjaer2, Soeren Tvilsted3, Steven E Schild4, Dirk Rades5. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 2. Neurological Department, Zealand University Hospital, Roskilde, Denmark. 3. Research Projects and Clinical Optimization, Zealand University Hospital, Koege, Denmark. 4. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A. 5. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany dirk.rades@uksh.de.
Abstract
BACKGROUND/AIM: Seizures impair patients' quality of life. The prognostic role of pre-treatment seizures in patients with 1-3 cerebral metastases receiving local therapies plus whole-brain radiotherapy (WBRT) was investigated. PATIENTS AND METHODS: In 249 patients, prevalence, risk factors and associations of pre-treatment seizures with survival were retrospectively evaluated. Age, gender, performance score, tumor type, number of lesions, extra-cerebral metastases, and time from tumor diagnosis to treatment of cerebral metastasis were analyzed for associations with seizures. These characteristics and pre-treatment seizures were also analyzed for associations with survival. RESULTS: The prevalence of pre-treatment seizures was 24.1%. Trends for associations were found between seizures and gender or performance score. On multivariate analysis, age (p=0.008), performance score (p=0.004), tumor type (p<0.001) and extra-cerebral metastasis (p<0.001) were significantly associated with survival. CONCLUSION: Seizures were comparably common prior to local therapies plus WBRT for cerebral metastases. No factor was found to be significantly associated with seizures, and seizures were not associated with survival. Copyright
BACKGROUND/AIM: Seizures impair patients' quality of life. The prognostic role of pre-treatment seizures in patients with 1-3 cerebral metastases receiving local therapies plus whole-brain radiotherapy (WBRT) was investigated. PATIENTS AND METHODS: In 249 patients, prevalence, risk factors and associations of pre-treatment seizures with survival were retrospectively evaluated. Age, gender, performance score, tumor type, number of lesions, extra-cerebral metastases, and time from tumor diagnosis to treatment of cerebral metastasis were analyzed for associations with seizures. These characteristics and pre-treatment seizures were also analyzed for associations with survival. RESULTS: The prevalence of pre-treatment seizures was 24.1%. Trends for associations were found between seizures and gender or performance score. On multivariate analysis, age (p=0.008), performance score (p=0.004), tumor type (p<0.001) and extra-cerebral metastasis (p<0.001) were significantly associated with survival. CONCLUSION:Seizures were comparably common prior to local therapies plus WBRT for cerebral metastases. No factor was found to be significantly associated with seizures, and seizures were not associated with survival. Copyright
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: Stefan Huttenlocher; Lena Sehmisch; Steven E Schild; Oliver Blank; Dagmar Hornung; Dirk Rades Journal: Anticancer Res Date: 2014-10 Impact factor: 2.480
Authors: Adela Wu; Jon D Weingart; Gary L Gallia; Michael Lim; Henry Brem; Chetan Bettegowda; Kaisorn L Chaichana Journal: World Neurosurg Date: 2017-05-13 Impact factor: 2.104
Authors: Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: JAMA Date: 2016-07-26 Impact factor: 56.272
Authors: Fabian Wolpert; Anna Lareida; Robert Terziev; Bettina Grossenbacher; Marian C Neidert; Patrick Roth; Rositsa Poryazova; Lukas L Imbach; Emilie Le Rhun; Michael Weller Journal: Neuro Oncol Date: 2020-05-15 Impact factor: 12.300
Authors: Dirk Rades; Oliver Blanck; Mai Trong Khoa; Pham VAN Thai; Nguyen Quang Hung; Liesa Dziggel; Steven E Schild Journal: In Vivo Date: 2018 Mar-Apr Impact factor: 2.155